Institut National de la Santé et de la Recherche Médicale (INSERM)

L'invention concerne un nouveau procédé de cyclisation d'une protéine d'intérêt utilisant une étiquette protéique constituée d'un peptide spécifique (NUFIP1 ou TAH1) et de son récepteur protéique (ZNHIT3 ou PIH1, respectivement) fusionnés respectivement aux extrémités N- et C-terminales de ladite protéine d'intérêt, et la protéine de fusion cyclisée résultante. Cela permet d'augmenter la thermostabilité et/ou d'aider à l'expression de protéines recombinantes et/ou d'aider à la purification de protéines recombinantes d'intérêt rendues plus solubles pour un meilleur rendement de production.

The present invention relates to a microfluidic device for biosensor and a microfluidic chip comprising several devices and thus biosensors.The microfluidic device comprising at least one microfluidic channel (10) comprising a first end opening (2) and at least a second end opening (3), and at least one biosensor (20) of a substrate arranged in the microfluidic channel (10), the microfluidic device comprises at least one reservoir (30) intended to receive a biosensor optimization solution (4) and comprising an opening (31) in fluidic communication with the microfluidic channel (10) and at least one microvalve (32) arranged between the microfluidic channel (10) and the reservoir (30) in such a way as to control the fluidic connection of the reservoir (30) to the microfluidic channel (10). It will be applied in vitro or in vivo for the detection of substrate or biomarker. Microfluidic devices or the microfluidic chip can be used to monitor the presence or level of substrate or biomarker.

The invention relates to a human pluripotent stem cell-derived, in vitro generated, retinal tissue characterized in that CHD1L activity is decreased. The invention also relates to methods for obtaining the retinal tissue and methods using the same.

The present invention relates to a method comprising the step detecting in a sample an antibody binding specifically to NECAB1, an antibody binding specifically to NECAB1, a carrier such as a diagnostically useful carrier with a solid phase with an immobilized polypeptide comprising an antigen or at least one epitope thereof or a variant of the antigen or epitope thereof, wherein the antigen is NECAB1, and a use of the antibody for diagnosing an autoimmune disease or a cancer.

The present invention relates to Engrailed protein, a nucleic acid encoding Engrailed protein and compositions comprising the same for use in treating or preventing diseases associated with accumulation of TDP-43 in the cell, particularly in the cell cytoplasm. Also provided herein are in vitro methods of selecting a subject for such therapy by detecting cellular accumulation of TDP-43, particularly cellular cytoplasmic accumulation, in a biological sample of the subject. Also provided herein are in vitro methods of following a subject treated with such therapy by measuring cellular accumulation, particularly cellular cytoplasmic accumulation, of TDP-43 in a biological sample of the treated subject.

Compounds of formula (I):or their pharmaceutically acceptable salts, hydrates, solvates, esters or their optical isomers, racemates, diastereoisomers, enantiomers, tautomers, or a mixture thereof; said compounds exhibits anti-plasmidal activities, in particular for the treatment of malaria diseases.

The present application deals with the quantitative detection of HERV ENV in a sample such as serum, more particularly the detection of HERV-W ENV or HERV-K ENV.

Un appareil d'imagerie ultrasonore tridimensionnelle (1) d'une région d'intérêt d'un être vivant comprend:- une sonde d'imagerie ultrasonore (100) comportant une pluralité de transducteurs ultrasonores élémentaires (102) répartis en un ensemble de groupes de transducteurs élémentaires (107), un circuit électronique d'émission (120) et un circuit électronique de réception (130) reliés aux transducteurs élémentaires (102);- un système de contrôle (140) communiquant avec la sonde (100);- ledit système de contrôle (140) étant configuré pour programmer pour chaque tir :(a) le circuit électronique d'émission (120) de manière à adresser un ensemble de transducteurs élémentaires pour l'émission d'une onde ultrasonore non focalisée, et(b) le circuit électronique de réception (130) de manière à adresser l'ensemble de groupes de transducteurs élémentaires ou une distribution de transducteurs élémentaires pour former des sous-ouvertures de réception apte à converger les ondes rétrodiffusées en un point focal situé derrière la sonde, du côté opposé à la région d'intérêt à imager.

The invention concerns a method for identifying cognate pairs of a ligand species and a receptor species, comprising co-compartmentalising ligand species and receptor species to form a set of microreactors, each microreactor comprising at least one ligand species and preferably at least one receptor species; assaying the recognition between ligands and receptors in each microreactor and based on this assay, classifying each microreactor as positive when at least one ligand species and at least one receptor species in the microreactor recognize one with the other or negative when no ligand species and no receptor species recognize in the microreactor; identifying ligand species and receptor species contained in each positive microreactor; establishing a subset of positive microreactors containing the same receptor species; determining the probability that in a given subset of positive microreactors containing the same receptor species, the ligand species recognizing the receptor species corresponds to the most frequent co-compartmentalized ligand species; and if the determined probability is greater than a predetermined threshold, identifying as a cognate pair the receptor species and the most frequent co-compartmentalized ligand species.

The present invention relates to a combination comprising at least one 5-HT2A receptor antagonist and at least one 5-HT3 receptor antagonist. The present invention also relates to a pharmaceutical composition comprising at least one 5-HT2A receptor antagonist and at least one 5-HT3 receptor antagonist, and optionally at least one other active ingredient. The present invention to a kit of parts comprising at least one 5-HT2A receptor antagonist and at least one 5-HT3 receptor antagonist as a combined preparation for simultaneous, separate or sequential use, and to the combination or the pharmaceutical composition of the invention for medical use.